Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension

Clinical Ophthalmology

Volumn 4, Issue 1, 2010, Pages 163-170

  Aihara, Makoto ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Intraocular pressure; Normal tension glaucoma; Open angle glaucoma; Receptor affinity

Indexed keywords

BIMATOPROST; LATANOPROST; PLACEBO; PROSTAGLANDIN DERIVATIVE; PROSTANOID RECEPTOR; TAFLUPROST; TAPROS; TIMOLOL; TRAVOPROST; UNCLASSIFIED DRUG;

CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SOLUTION; DRUG STORAGE; DRUG STRUCTURE; EYE DISEASE; EYE IRRITATION; EYELID DISEASE; HAIR DISEASE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE ABNORMALITY; IRIS DISEASE; JAPAN; NONHUMAN; OPEN ANGLE GLAUCOMA; PRURITUS; REVIEW; SINGLE DRUG DOSE;

EID: 77953436554     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/opth.s6368     Document Type: Review

References (24)

1. Resul B, Stjernschantz J. Structure-activity relationships of prostaglan din analogues as ocular hypotensive agents. Curr Opin Ther. 1993;3: 781-795.
2. Fukano Y, Kawazu K. Disposition and metabolism of a novel prostanoid antiglaucoma medication, tafluprost, following ocular administration to rats. Drug Metab Dispos. 2009;37:1622-1634.
3. Takagi Y, Nakajima T, Shimazaki A, et al. Pharmacological character istics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp Eye Res. 2004;78:768-776.
4. Sharif NA, Kelly CR, Crider JY, et al. Ocular hypotensive FP pros taglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther. 2003;19:501-515.
5. Goh Y, Kishino J. Pharmacological characterization of prostaglandin related ocular hypotensive agents. Jpn J Ophthalmol. 1994;38: 236-245.
6. Woodward DF, Krauss AH-P, Chen J, et al. The pharmacology of bima toprost. Surv Ophthalmol. 2001;45(Suppl 4):S337-S345.
7. Liang Y, Woodward DF, Guzman VM, et al. Identification and phar macological characterization of the prostaglandin FP receptor and FP receptor variant complexes. Br J Pharmacol. 2008;154:1079-1093.
8. Ota T, Aihara M, Narumiya S, et al. The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. Invest Ophthalmol Vis Sci. 2005;46:4159-4163.
9. Ota T, Aihara M, Saeki T, et al. The IOP-lowering effects and mecha nism of action of tafluprost in prostanoid receptor-deficient mice. Br J Ophthalmol. 2007;91:673-676.
10. M, Kurashima H, Ishida N, et al. Effect of tafluprost on the intraocular pressure in latanoprost low-responder monkeys. In World Glaucoma Congress, Boston, USA; 2009.
11. Izumi N, Nagaoka T, Sato E, et al. Short-term effects of topical tafluprost on retinal blood flow in cats. J Ocul Pharmacol Ther. 2008;24:521-526.
12. Kurashima H, Akaishi T, Odani-Kawabata N, et al. The effect of pros taglandins on endothelin-1-induced impairment of ocular blood flow in rabbits. In: Annual Meeting of The Association for Research in Vision and Ophthalmology, Fort Lauderdale, USA; 2008.
13. Dong Y, Watabe H, Su G, et al. Relaxing effect and mechanism of tafluprost on isolated rabbit ciliary arteries. Exp Eye Res. 2008;87: 251-256.
14. Kanamori A, Naka M, Fukuda M, et al. Tafluprost protects rat retinal ganglion cells from apoptosis in vitro and in vivo. Graefes Arch Clin Exp Ophthalmol. 2009;247:1353-1360.
15. Sutton A, Gilvarry A, Ropo A. A comparative, placebo-controlled study of prostanoid fluoroprostaglandin-receptor agonists tafluprost and latanoprost in healthy males. J Ocul Pharm Ther. 2007;23:359-365.
16. Sutton A, Gouws P, Ropo A. Tafluprost, a new potent prostanoid receptor agonist: A dose-response study on pharmacodynamics and tolerability in healthy volunteers. Int J Clin Pharm Ther. 2008;46:400-406.
17. Uusitalo HMT, Pillunat LE, Baudouin C, et al. Phase III, 24-month study investigating the efficacy and safety of tafluprost vs latanoprost in patients with open-angle glaucoma or ocular hypertension. Acta Ophthalmologica. 2008;86(S243).
18. Egorov E, Ropo A. Adjunctive use of tafluprost with timolol provides additive effects for reduction of intraocular pressure in patients with glaucoma. Eur J Ophthalmol. 2009;19:214-222.
19. Uusitalo H, Kaarniranta K, Ropo A. Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers. Acta Ophthalmol Suppl. 2008;242:7-13.
20. Kuwayama Y, Komemusi S. Phase III confirmatory study of 0.0015% DE-085 (Tafluprost) ophthalmic solution as compared to 0.005% Latanoprost ophthalmic solution in patients with open-angle glaucoma or ocular hypertension. Atarashii Ganka. 2008;25:1595-1602.
21. Iwase A, Suzuki Y, Araie M, et al. The prevalence of primary open angle glaucoma in Japanese: The Tajimi Study. Ophthalmology. 2004;111:1641-1648.
22. Hamacher T, Airaksinen J, Saarela V, et al. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: Results from a pharmacodynamics analysis. Acta Ophthalmol Suppl. 2008;242:14-19.
23. Yamamoto T, Iwase A, Araie M, et al. The Tajimi Study Report 2: Prevalence of primary angle closure and secondary glaucoma in a Japanese population. Ophthalmology. 2005;112:1661-1669.
24. Hyodo R, Mizoue S, Kawasaki S, et al. Investigation of glaucoma eyedrop bottle usability by elderly patients. Journal of the Eye. 2007;24:371-376.